Matteo S. Carlino, MBBS, PhD, FRACP, discusses how neoantigen-specific T cells link to intismeran autogene’s KEYNOTE-942 recurrence benefit.
Matteo S. Carlino, MBBS, PhD, FRACP
Advertisement
Articles by Matteo S. Carlino, MBBS, PhD, FRACP
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Iberdomide Plus Daratumumab/Dexamethasone for R/R Myeloma
2
Dr Banerjee on the FDA Approval of Iberdomide Plus Daratumumab/Dexamethasone in R/R Myeloma
3
Dr Carlino on 5-Year Data With Intismeran Plus Pembrolizumab in Resected Melanoma
4
Dr Garg on a Phase 3 Study of Proton Therapy in Head and Neck Cancer
5